Trazodone on OSA Endotypes
Eligible age
21–70 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Some OSA patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this protocol the investigators will test the effect of trazodone administered before sleep on OSA traits and OSA severity during sleep.
Sponsor: Brigham and Women's Hospital
You may qualify if…
- ✓ Moderate-to-severe OSA (AHI ≥ 15 events/hr)
You may not qualify if…
- ✕ All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements.
- ✕ Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).
- ✕ Use of SNRIs/SSRIs.
- ✕ Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.
- ✕ Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:
- ✕ Other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias.
- ✕ Hypersensitivity to the study drug (angioedema or urticaria)
- ✕ Contraindications to DAW2020
Where it's recruiting
Boston
Source: ClinicalTrials.gov · NCT06286189 · last updated 2025-02-06